The PennZone

  • Home
  • Music
  • Entertainment
  • Marketing
  • Education
  • Non-profit
  • Technology
  • Event
  • Books

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
  • OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
  • Contracting Resources Group Named to Inc. 5000 for the Ninth Time
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
  • Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
  • Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
  • Colonial Nissan Earns Capital One Top Performing Dealership Award
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • Logistics Expert Asks A Question Biology Has Overlooked: How Evolution Assembles Coordinated Novelty
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
  • Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
  • Leading PDR Training Courses in Canada: Learn Paintless Dent Repair with PDR Academy & Tint Academy
  • Move in this Fall! New Released Quick Move-In Townhomes at Heritage at South Brunswick with Limited-Time Incentives
  • Rebecca L. Francis, Founder of the Rebecca Francis Team, Named to Lehigh Valley Business' LVB 300
  • Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
  • Imagen Golf & Top 100 Coach Daniel Guest Voted Best Golf Instruction Firm of the Year 2026
  • Q1 2026 Arizona Technology Industry Impact Report Recaps Advanced Manufacturing Growth, High-Value Jobs and Workforce Investment
  • Former Prosecutor Opens Stegall Law in Summerville
  • Vboost Celebrates 14 years of Automotive Viral Marketing
  • M.C. Weeks, Inc. Marks 80 Years of Family Ownership and Brand Refresh
  • Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
  • SMACK Fighting Championships Debuts a New Sports Concept in Philadelphia
  • Tickeron Highlights AI Trading Agent Performance Across Multiple Market Sectors
  • Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
  • Crownlight Strategies® Announces Federal Trademark Registration
  • New Book Calls 'Sense of Belonging' the Missing Link in Student Success
  • Igbozue Connecticut USA Celebrates 2026 Summer Family Picnic
  • KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
  • Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
  • Chuckie F. Mahoney Memorial Foundation Awards Nearly $40,000 in School Grants

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 269
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
  • New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity

Similar on PennZone

  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
  • Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
  • Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
  • KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
  • Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
  • Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
  • Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
  • XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us